In newly diagnosed FLT3-ITD or FLT3-TKD mutated AML, the RATIFY trial demonstrated that the addition of midostaurin to standard induction therapy prolonged OS [13], also independently from the NPM1 mutation/FLT3-ITD allelic ratio combinations [8], resulting in midostaurin as a new standard of care. The gene discussed is FLT3; the disease is acute myeloid leukemia.